NASDAQ : TMDX
TransMedics Group, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 67.12 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.33B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.29B |
| Enterprise Value | 2.68B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 34.68M |
| Shares Outstanding | 34.68M |
| Shares Change (YoY) | +1.53% |
| Shares Change (QoQ) | +12.48% |
| Owned by Insiders (%) | 3.19% |
| Owned by Institutions (%) | 103.01% |
| Float | 33.56M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 16.44 |
| Forward PE | 36.57 |
| PS Ratio | 3.42 |
| Forward PS | 2.83 |
| PB Ratio | 4.41 |
| P/TBV Ratio | 4.52 |
| P/FCF Ratio | 28.95 |
| P/OCF Ratio | 15.68 |
| PEG Ratio | 0.73 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 17.69 |
| EV / Sales | 4.01 |
| EV / EBITDA | 23.21 |
| EV / EBIT | 32.88 |
| EV / FCF | 33.95 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.62 |
| Quick Ratio | 5.87 |
| Debt / Equity | 1.67 |
| Debt / EBITDA | 6.99 |
| Debt / FCF | 10.98 |
| Interest Coverage | 3.84 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 36.28% |
| Return on Assets (ROA) | 4.33% |
| Return on Invested Capital (ROIC) | 9.02% |
| Return on Capital Employed (ROCE) | 5.97% |
| Weighted Average Cost of Capital (WACC) | 11.29% |
| Revenue Per Employee | $744,396 |
| Profits Per Employee | $168,930 |
| Employee Count | 898 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 5.46 |
Taxes
| Measure | Value |
|---|
| Income Tax | -79.15M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.93 |
| 52-Week Price Change | -50.87% |
| 50-Day Moving Average | 81.65 |
| 200-Day Moving Average | 94.48 |
| Relative Strength Index (RSI) | 28.92 |
| Average Volume (20 Days) | 875,294 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.77M |
| Short Previous Month | 8.55M |
| Short % of Shares Out | 25.29% |
| Short % of Float | 26.13% |
| Short Ratio (days to cover) | 11.14 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 668.47M |
| Gross Profit | 392.35M |
| Operating Income | 81.61M |
| Pretax Income | 72.55M |
| Net Income | 151.70M |
| EBITDA | 115.63M |
| EBIT | 81.61M |
| Earnings Per Share (EPS) | $4.01 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 472.68M |
| Total Debt | 867.72M |
| Net Cash | -395.05M |
| Net Cash Per Share | -$11.39 |
| Equity (Book Value) | 518.05M |
| Book Value Per Share | 14.96 |
| Working Capital | 552.84M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 145.93M |
| Capital Expenditures | -66.89M |
| Depreciation & Amortization | 34.02M |
| Net Borrowing | n/a |
| Free Cash Flow | 79.04M |
| FCF Per Share | $2.28 |
Margins
| Measure | Value |
|---|
| Gross Margin | 58.69% |
| Operating Margin | 12.21% |
| Pretax Margin | 10.85% |
| Profit Margin | 22.69% |
| EBITDA Margin | 17.30% |
| EBIT Margin | 12.21% |
| FCF Margin | 11.82% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.53% |
| Shareholder Yield | -1.53% |
| Earnings Yield | 6.08% |
| FCF Yield | 3.45% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $98.73 |
| Price Target Difference | 49.61% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 18.81% |
| EPS Growth Forecast (3Y) | 7.96% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.33 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |